Methylprednisolone sodium succinate
MRCTA,ECFAH of FMU[2024]368-1
Phase 3 small_molecule active
Quick answer
Methylprednisolone sodium succinate for Acute Ischemic Stroke is a Phase 3 program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- First Tracks Biotherapeutics
- Indication
- Acute Ischemic Stroke
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active